reports
Novo Nordisk phase 2 trial with amycretin reports significant weight l...
Novo Nordisk phase 2 trial with amycretin reports significant weight loss and HbA1c reduction in type 2 diabetes Amycretin showed statistically significant weight loss of up to 14.5% at 36 weeksAmycretin demonstrated statistically significant reductions in HbA1c with up to 89.1% achieving HbA1c levels below 7%Amycretin appeared to have a safe and well-tolerated profile consistent with incretin and amylin-based therapies Bagsværd, Denmark, 25 November 2025 – Novo Nordisk today announced positive headline results from a phase 2 clinical trial with amycretin in people with type 2 diabetes. Th...
- Carole Braudeau
BMW BAYERISCHE MOTOREN WERKE AKTIENGESELLSCHAFT
ETL EUTELSAT COMMUNICATIONS SA
RNO RENAULT SA
DAI DAIMLER AG
MF WENDEL SE
NEX NEXANS SA
VOW3 VOLKSWAGEN AG PREF
EZJ EASYJET PLC
RACE FERRARI NV
NEXI NEXI S.P.A.
VRLA VERALLIA SAS
STLA STELLANTIS N.V.
CIRSA CIRSA ENTERPRISES S.A.
- Carole Braudeau
BMW BAYERISCHE MOTOREN WERKE AKTIENGESELLSCHAFT
ETL EUTELSAT COMMUNICATIONS SA
RNO RENAULT SA
DAI DAIMLER AG
MF WENDEL SE
NEX NEXANS SA
VOW3 VOLKSWAGEN AG PREF
EZJ EASYJET PLC
RACE FERRARI NV
NEXI NEXI S.P.A.
VRLA VERALLIA SAS
STLA STELLANTIS N.V.
CIRSA CIRSA ENTERPRISES S.A.
- Delphine Brault
- Jean-François Granjon
- Marc Lavaud
- Nathan Mietlicki
SU SCHNEIDER ELECTRIC SE
KNEBV KONE OYJ CLASS B
G1A GEA GROUP AG
ABB ABB LTD.
RXL REXEL SA
CPG COMPASS GROUP PLC
OERL OC OERLIKON CORPORATION AG
ALO ALSTOM SA
SCHP SCHINDLER HOLDING AG PREF
NEX NEXANS SA
EZJ EASYJET PLC
SUN SULZER AG
KRN KRONES AG
DOKA DORMAKABA HOLDING AG
KGX KION GROUP AG
ASSA B ASSA ABLOY AB CLASS B
BCHN BURCKHARDT COMPRESSION HOLDING AG
PRY PRYSMIAN S.P.A.
ANDR ANDRITZ AG
BOSN BOSSARD HOLDING AG
SFSN SFS GROUP AG
JUN3 JUNGHEINRICH AG PREF
SIE SIEMENS AG
NKT NKT A/S
DUE DURR AG
VOS VOSSLOH AG
SANT S&T AG
CAF CONSTRUCCIONES Y AUXILIAR DE FERROCARRILES S.A.
KBX KNORR-BREMSE AG
PRX PROSUS N.V. CLASS N
SRAIL STADLER RAIL AG
ENR SIEMENS ENERGY AG
ATCO A ATLAS COPCO AB
STMN STRAUMANN HOLDING AG
ACLN ACCELLERON INDUSTRIES LTD
NOVO B NOVO NORDISK A/S
AGN AEGON N.V.
PFSE PFISTERER HOLDING SE
- Delphine Brault
- Jean-François Granjon
- Marc Lavaud
- Nathan Mietlicki
SU SCHNEIDER ELECTRIC SE
KNEBV KONE OYJ CLASS B
G1A GEA GROUP AG
ABB ABB LTD.
RXL REXEL SA
CPG COMPASS GROUP PLC
OERL OC OERLIKON CORPORATION AG
ALO ALSTOM SA
SCHP SCHINDLER HOLDING AG PREF
NEX NEXANS SA
EZJ EASYJET PLC
SUN SULZER AG
KRN KRONES AG
DOKA DORMAKABA HOLDING AG
KGX KION GROUP AG
ASSA B ASSA ABLOY AB CLASS B
BCHN BURCKHARDT COMPRESSION HOLDING AG
PRY PRYSMIAN S.P.A.
ANDR ANDRITZ AG
BOSN BOSSARD HOLDING AG
SFSN SFS GROUP AG
JUN3 JUNGHEINRICH AG PREF
SIE SIEMENS AG
NKT NKT A/S
DUE DURR AG
VOS VOSSLOH AG
SANT S&T AG
CAF CONSTRUCCIONES Y AUXILIAR DE FERROCARRILES S.A.
KBX KNORR-BREMSE AG
PRX PROSUS N.V. CLASS N
SRAIL STADLER RAIL AG
ENR SIEMENS ENERGY AG
ATCO A ATLAS COPCO AB
STMN STRAUMANN HOLDING AG
ACLN ACCELLERON INDUSTRIES LTD
NOVO B NOVO NORDISK A/S
AGN AEGON N.V.
PFSE PFISTERER HOLDING SE
- ING Helpdesk
Benelux Morning Notes
ABN AMRO: CMD targets at higher end, bold FTE cut to clinch 55% C/I ratio, lower CoRisk. D'Ieteren: Key Belron US glass supplier Fuyao connected to US labour allegations. Elia: Preview 3Q25 update; fine-tuning guidance to upper end of range?. NSI: KPN to leave Glass House, c.7.5% additional vacancy. SBM Offshore: Another step towards SEAP 1+2 FPSO awards. Universal Music Group: Spotify to increase its US subscription prices in 1Q26
- Wim Lewi
Switch on the Robots Automation and Energy Investments in Logistic/Ind...
Automation and Energy investments increase the value per sqm of landbank. Tenants are inclined to sign longer lease contracts to protect their significant investments. We expect to see more large warehouse automation projects over the next 12-18 months as the ROI increases thanks to technological innovations. The decision process seems to take longer due to the size of the investments. We believe the logistic segment offers an interesting investment opportunity. WDP trades at only 3% premium...
- Martial Descoutures
- Martial Descoutures
FERRARI N.V.: PERIODIC REPORT ON THE BUYBACK PROGRAM
FERRARI N.V.: PERIODIC REPORT ON THE BUYBACK PROGRAM Maranello (Italy), November 24, 2025 – Ferrari N.V. (NYSE/EXM: RACE) (“Ferrari” or the “Company”) informs that the Company has purchased, under the Euro 360 million share buyback program announced on July 31, 2025, as the eighth tranche of the multi-year share buyback program of approximately Euro 2 billion expected to be executed by 2026 in line with the disclosure made during the 2022 Capital Markets Day (the “Eighth Tranche”), the additional common shares - reported in aggregate form, on a daily basis - on the Euronext Milan (EXM) and ...
Novo Nordisk A/S: Evoke phase 3 trials did not demonstrate a statistic...
Novo Nordisk A/S: Evoke phase 3 trials did not demonstrate a statistically significant reduction in Alzheimer's disease progression Bagsværd, Denmark, 24 November 2025 – Novo Nordisk today announced the top-line results from the 2-year primary analysis of evoke and evoke+ phase 3 trials in early-stage symptomatic Alzheimer’s disease. The two trials were randomised, double-blinded, enrolled a total of 3808 adults and evaluated the efficacy and safety of oral semaglutide compared to placebo on top of standard of care. The decision to pursue an Alzheimer’s disease indication with semaglutide w...
Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, exe...
Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons Bagsværd, Denmark, 17 November 2025 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse. The company’s board members, executives and their associated persons have reported the transactions to Novo Nordisk. 1 Details of the person discharging managerial responsibilities/person closely associated a)Name of ...
FERRARI N.V.: PERIODIC REPORT ON THE BUYBACK PROGRAM
FERRARI N.V.: PERIODIC REPORT ON THE BUYBACK PROGRAM Maranello (Italy), November 17, 2025 – Ferrari N.V. (NYSE/EXM: RACE) (“Ferrari” or the “Company”) informs that the Company has purchased, under the Euro 360 million share buyback program announced on July 31, 2025, as the eighth tranche of the multi-year share buyback program of approximately Euro 2 billion expected to be executed by 2026 in line with the disclosure made during the 2022 Capital Markets Day (the “Eighth Tranche”), the additional common shares - reported in aggregate form, on a daily basis - on the Euronext Milan (EXM) and ...
Resolutions from the Extraordinary General Meeting of Novo Nordisk A/S
Resolutions from the Extraordinary General Meeting of Novo Nordisk A/S Bagsværd, Denmark, 14 November 2025 - Today, Novo Nordisk A/S held its Extraordinary General Meeting, which was convened to elect new members of the Board of Directors. At the Extraordinary General Meeting, Helge Lund (chair), Henrik Poulsen (vice chair) and the Board members Laurence Debroux, Andreas Fibig, Sylvie Grégoire, Christina Law and Martin Mackay stepped down from the Board of Directors. Resolutions adopted at the Extraordinary General MeetingElections Election of Lars Rebien Sørensen as chair of the Board o...
Novo Nordisk A/S: Candidate for the Board of Directors will not seek e...
Novo Nordisk A/S: Candidate for the Board of Directors will not seek election Bagsværd, Denmark, 13 November 2025 – Today, it was announced that Mikael Dolsten will not seek election to the Board of Directors at the upcoming extraordinary general meeting on 14 November 2025, as otherwise announced in the notice convening the Extraordinary General Meeting. Earlier today, Mikael Dolsten, who most recently served as the Head of R&D at Pfizer, informed Novo Nordisk that, in spite of his desire to join, he has decided to withdraw his candidacy to the Novo Nordisk Board of Directors, both as a m...
- Marc Lavaud
- Martin Marandon-Carlhian
- Stephane Houri
MC LVMH MOET HENNESSY LOUIS VUITTON SE
MUV2 MUNICH REINSURANCE COMPANY
EOAN E.ON SE
RWE RWE AG
BAYN BAYER AG
SLHN SWISS LIFE HOLDING AG
BA. BAE SYSTEMS PLC
LEG LEG IMMOBILIEN AG
YPSN YPSOMED HOLDING AG
REC RECORDATI INDUSTRIA CHIMICA E FARMACEUTICA S.P.A.
POST OSTERREICHISCHE POST AG
BNR BRENNTAG SE
HAG HENSOLDT AG
- Marc Lavaud
- Martin Marandon-Carlhian
- Stephane Houri
MC LVMH MOET HENNESSY LOUIS VUITTON SE
MUV2 MUNICH REINSURANCE COMPANY
EOAN E.ON SE
RWE RWE AG
BAYN BAYER AG
SLHN SWISS LIFE HOLDING AG
BA. BAE SYSTEMS PLC
LEG LEG IMMOBILIEN AG
YPSN YPSOMED HOLDING AG
REC RECORDATI INDUSTRIA CHIMICA E FARMACEUTICA S.P.A.
BNR BRENNTAG SE
HAG HENSOLDT AG
- Olfa Taamallah
- Yan Derocles
- Olfa Taamallah
- Yan Derocles
Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, exe...
Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons Bagsværd, Denmark, 11 November 2025 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse. The company’s board members, executives and their associated persons have reported the transactions to Novo Nordisk. 1 Details of the person discharging managerial responsibilities/person closely associated a)Name of ...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.